Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trialAlbert M. Maguire, Jean Bennett, Gui‐Shuang Ying et al.|The Lancet|2009Cited by 857
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector AdministrationFrancesca Simonelli, Alberto Auricchio, Albert M. Maguire et al.|Molecular Therapy|2009Cited by 551
AAV2 Gene Therapy Readministration in Three Adults with Congenital BlindnessJean Bennett, Albert M. Maguire, Manzar Ashtari et al.|Science Translational Medicine|2012Cited by 390
Systemic AAV8-Mediated Gene Therapy Drives Whole-Body Correction of Myotubular Myopathy in DogsDavid L. Mack, Martin K. Childers, Karine Poulard et al.|Molecular Therapy|2017Cited by 109